Skip to main content
Advent Life SciencesPress Release

Advent Life Sciences Announces Appointment of Alain Huriez as Venture Partner

By 27 June 2012January 6th, 2023No Comments
Press Release.


27th June 2012, London: – Advent Life Sciences announced today the appointment of Alain Huriez MD, as a Venture Partner.   Alain brings 22 years of experience in management, drug development and financing in the life sciences sector, including as CEO of TcLand Expression and Neovacs, Associate Partner at Truffle Capital and Vice President at Quintiles.   Prior to this, he was a practising physician.   Alain has also been responsible for several initiatives in Europe within the areas of personalised medicine, biomarkers and high value diagnostics through his work as chairman of EPEMED, the European Personalised Medicine Association.

– Ends –

About Advent Life Sciences:
Advent Life Sciences is the dedicated Life Sciences team at Advent Venture Partners, one of Europe’s best established growth and venture capital firms.  Advent Life Sciences invests predominantly in early-stage and growth equity life sciences companies in the UK, Europe and the US.  It will back companies that have a first- or best-in-class approach in a range of sectors within the life sciences, including new drug discovery, enabling technologies, med-tech and diagnostics.

Advent Life Sciences is a leader in European life sciences venture capital.  Its investments include:  PowderMed, a therapeutic DNA vaccine company sold to Pfizer; Thiakis, an obesity treatment company acquired by Wyeth Pharmaceuticals; Respivert, a drug discovery company focused on respiratory diseases that was acquired by Johnson & Johnson; EUSA Pharma, a transatlantic speciality pharmaceutical company acquired by Jazz Pharmaceuticals; Avila Therapeutics, a biotechnology company developing targeted covalent drugs acquired by Celgene Corporation, Micromet, a biotechnology company acquired by Amgen and Algeta (OSE: ALGETA), an oncology company developing treatments for bone metastases and disseminated tumours.

For more information contact:

Advent Venture Partners
Josephine Defty
Ph: +44 (0) 20 7932 2116